TNFRSF9 and neoplasm: NKp30-CD28 TCRKO CAR T lymphocytes elicited a robust anti-tumor response and sustained control of tumor burden, whereas NKp30-CD137/TCRKO CAR T cells demonstrated partial and transient anti-tumor reactivity.